Announcements Trials

Browse Landscape

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Lymphoma, Non-Hodgkin 4 Lymphoma, Follicular 4 Lymphoma, Mantle-Cell 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma, B-Cell, Marginal Zone 2 Lymphoma, B-Cell 2 Lymphoma 2 Waldenstrom Macroglobulinemia 1 Recurrence 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Leukemia, Prolymphocytic 1 Leukemia, Lymphocytic, Chronic, B-Cell 1 Leukemia 1 Dendritic Cell Sarcoma, Interdigitating 1 Burkitt Lymphoma 1

Interventions

Rituximab 16 Cyclophosphamide 16 Peripheral Blood Stem Cell Transplantation 11 fludarabine phosphate 10 Cytarabine 9 Methotrexate 8 Vincristine 7 blinatumomab 6 Filgrastim 6 Etoposide 6 fludarabine 5 Prednisone 5 Mycophenolic Acid 5 Lenalidomide 5 Dexamethasone 5 Cyclosporine 5 merphos 4 Whole-Body Irradiation 4 Radiotherapy 4 Ifosfamide 4 Carboplatin 4 venetoclax 3 romidepsin 3 prednylidene 3 deltacortene 3 Spinal Puncture 3 Microarray Analysis 3 Melphalan 3 Magnetic Resonance Spectroscopy 3 Inotuzumab Ozogamicin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Burkitt Lymphoma × veltuzumab × Clear all

NCT01279707 2014-07-14

MARALL

Queen Mary University of London

Phase 1/2 Unknown

Burkitt Lymphoma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon ⚡